Cameron, David

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 2.

Journal Article

Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6

Cameron, David; Brown, Julia; Dent, Rebecca; Jackisch, Christian; Mackey, John; Pivot, Xavier; Steger, Guenther G.; Suter, Thomas M.; Toi, Masakazu; Parmar, Mahesh; Laeufle, Rita; Im, Young-Hyuck; Romieu, Gilles; Harvey, Vernon; Lipatov, Oleg; Pienkowski, Tadeusz; Cottu, Paul; Chan, Arlene; Im, Seock-Ah; Hall, Peter S.; ... (2013). Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. The lancet oncology, 14(10), pp. 933-942. Elsevier 10.1016/S1470-2045(13)70335-8

This list was generated on Wed Feb 26 03:57:22 2020 CET.
Provide Feedback